Due to undesired dose-related side effects (i.e. hypotension) associated with systemic delivery of recombinant IL-1α [24], we encapsulated IL-1α in a CPH:SA (1,6‐bis‐(p‐carboxyphenoxy)‐hexane: sebacic acid (20:80)) polymer and previously reported that these CPH:SA IL-1αMPs (IL-1αMPs) released IL-1α in a slow and sustained manner, with no toxicity or loss in bioactivity in HNSCC tumor-bearing mice [19]. The gene discussed is IL1A; the disease is neoplasm.